Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97:38-43. Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

Invasive Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATelet Inhibition and patient Outcomes trial Outcomes in.
Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
Paul Gurbel, Kevin Bliden, Tania Gesheff, Yvonne Kreutz, Udaya Tantry Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Baltimore, Maryland,
Should we Monitor Anti-Platelet Treatment? Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.
Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease Dominick J. Angiolillo,
Prasugrel Background and PRINCIPLE – TIMI 44 Stephen D. Wiviott, MD Cardiovascular Division Brigham and Women’s Hospital Assistant Professor of Medicine.
Clopidogrel Response Variability and
Dominick J. Angiolillo, MD, PhD Director of Cardiovascular Research Assistant Professor of Medicine University of Florida College of Medicine – Jacksonville,
Point of Care Platelet Function Testing – Is There Still Value?
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.
S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.
Clopidogrel for All – Or Tailored Therapy? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton.
Post-PCI/MI Thrombotic Events – A Plateletcentric Problem!!!!
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield, UK Stent thrombosis Future directions.
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the Plavix Response in Coronary Intervention (PRINC) trial ACTRN
Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:
What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.
(The CLEAR PLATELETS-2 Study) Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation.
Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Use of PPIs during Clopidogrel Therapy Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University February 26,
Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention Published in Journal of the American College of Cardiology.
PPIs reduces the antiplatelt effects of clopidogrel: According to a 2007 survey, clopidogrel is the sixth most commonly.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Antiplatelet Resistance: What Does it Mean.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Update on Novel Antiplatelet Agents Under.
Copyright ©2007 American Heart Association Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association Wiviott SD et al, Circulation.
Do We Need Platelet Function Assays?
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
New Anti-platelet Agents
The DISPERSE2 Trial Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared.
PhenGene P2Y12 Test.
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
How to Switch from Clopidogrel to Prasugrel or Ticagrelor
Randomisation before planned PCI with DES (n=2500)
The DISPERSE2 Trial Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared.
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.
Matthew J. Price MD Director, Cardiac Catheterization Laboratory,
Interactions with Other Medications and Platelet Turnover
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
Platelet Function Testing: Which one Should we Perform and
We Should Tailor Antiplatelet Therapy Based on Platelet Function Testing and Genotyping Paul A. Gurbel Sinai Center for Thrombosis Research Baltimore,
Introduction We have previously reported a significant incidence of clopidogrel resistance in patients post-elective coronary stenting treated with a standard.
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel.
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Glenn N. Levine et al. JACC 2016;68:
Figure 3 Metabolism pathway of antiplatelet agents
Glenn N. Levine et al. JACC 2016;68:
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Orlando, March , American College of Cardiology
Impact of Platelet Reactivity Following Clopidogrel Administration
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Presentation transcript:

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of Treatment % Platelet Aggregation (LTA-ADP 20  mol/L) Number of Patients Bleeding risk Ischemic risk

Clinical Relevance of Clopidogrel Non-responsiveness NFunctional ParameterClinical Relevance Mueller et al. Thromb Haemost ↓ inhibition of platelet aggregation Stent thrombosis Barragan et al. CCI ↑ P2Y 12 reactivity ratio (VASP-levels) Stent thrombosis Gurbel et al. JACC ↑ P2Y 12 reactivity ratio; ↑platelet aggregation; ↑ stimulated GPIIb/IIIa expression Stent thrombosis Ajzenberg et al. JACC ↑ shear-induced platelet aggregation Stent thrombosis Angiolillo DJ et al. Am J Cardiov Drugs Stent Thrombosis

NFunctional ParameterClinical Relevance Matezky et al. Circulation ↑ platelet aggregation (4 th quartile) Post-primary PCI ischemic events (6 months) Gurbel et al. JACC ↑ periprocedrual platelet aggregation Post-PCI ischemic events (6 months) Gurbel et al. Circulation ↑ periprocedrual platelet aggregation Myonecrosis and inflammation marker release Cuisset et al. J Thromb Haemost ↑ platelet aggregation Post-PCI ischemic events (30 days) Lev et al. JACC ↑ clopidogrel/aspirin-resistant patients Post PCI-myonecrosis Cuisset et al. JACC ↑ platelet aggregation Post-PCI ischemic events (30 days) Hocholzer et al. JACC 2006 Geisler et al. Eur Heart J 2006 Bliden et al. JACC ↑ platelet aggregation (3 rd & 4 th quartiles) ↓ platelet inhibition ↑ platelet aggregation Post-PCI ischemic events (30 days) Post-PCI ischemic events (3 months) Post-PCI ischemic events (12 months) Angiolillo DJ et al. Am J Cardiov Drugs Post-Stent Ischemic Events and Periprocedural Infarction Clinical Relevance of Clopidogrel Non-responsiveness

Cellular Factors Accelerated platelet turnover Reduced CYP3A metabolic activity Reduced CYP3A metabolic activity Increased ADP exposure Increased ADP exposure Up-regulation of the P2Y 12 pathway Up-regulation of the P2Y 12 pathway Up-regulation of the P2Y 1 pathway Up-regulation of the P2Y 1 pathway Up-regulation of P2Y–independent pathways Up-regulation of P2Y–independent pathways (collagen, epinephrine, TXA 2, thrombin) (collagen, epinephrine, TXA 2, thrombin) Clinical Factors Failure to prescribe/poor compliance Under-dosing Under-dosing Poor absorption Poor absorption Drug-drug interactions involving CYP3A4 Drug-drug interactions involving CYP3A4 Acute coronary syndrome Acute coronary syndrome Diabetes mellitus/insulin resistance Diabetes mellitus/insulin resistance Elevated body mass index Elevated body mass index Genetic Factors Polymorphisms of CYP Polymorphisms of GPIa Polymorphisms of GPIa Polymorphisms of P2Y 12 Polymorphisms of P2Y 12 Polymorphisms of GPIIIa Polymorphisms of GPIIIa Clopidogrel Response Variability Angiolillo DJ et al. J Am Coll Cardiol. 2007; 49:

78% 14% 8% P=0.04 Influence of Diabetes Mellitus on Clopidogrel-induced Antiplatelet Effects Angiolillo DJ et al. Diabetes. 2005;54: Non-responders (Platelet inhibition  10%) Low responders (Platelet inhibition 10-29%) Responders (Platelet inhibition >30%) 56% 6% 38% DMNo-DM Acute phase of treatment Long-term phase of treatment 24 hrs post 300 mg LD Angiolillo DJ et al. J Am Coll Cardiol 2006; Platelet aggregation (%) P=0.001 P< ADP 20  mol/L ADP 6  mol/L T2DMNo-DMT2DMNo-DM

Platelet Function According to Hypoglycemic Treatment Angiolillo DJ et al. J Am Coll Cardiol. 2006;48: % Platelet aggregation (LTA) ADP 6 µmol/L P< ADP 20 µmol/L P< NDMNIDDMIDDMNDMNIDDMIDDM

* >50% ADP (20  mol/L)-induced post-treatment platelet reactivity Type 2 diabetes mellitus patients with coronary artery disease on aspirin (81 mg) + clopidogrel (75 mg) therapy for ≥1 month Platelet function assessment to identify suboptimal and optimal responders Study Time Point 1 Platelet function assessment Study Time Point mg clopidogrel/day for 30 days (n=20) 75 mg clopidogrel/day for 30 days (n=20) Randomization Not eligible for randomization Platelet function assessment Study Time Point 2 75 mg clopidogrel/day for 30 days Inclusion Criteria Optimal responders Suboptimal responders * OPTIMUS Study: (Optimizing anti-Platelet Therapy In diabetes MellitUS) Angiolillo DJ et al. Circulation. 2007;115:

T1T2 T1 P=0.5 P< mg 150mg T2 P=0.32 P= ±9 67.4±6 52.3± ±7 Angiolillo DJ et al. Circulation. 2007;115: Primary Endpoint: Maximal ADP (20  mol/L) Platelet Aggregation Maximal ADP (20  mol/L) platelet aggregation (%) OPTIMUS Study: (Optimizing anti-Platelet Therapy In diabetes MellitUS)

OPTIMUS Prevalence of Patients Reaching Therapeutic P2Y 12 Target Levels (20  mol/L-induced Agg max ≤50%) 75 mg 150 mg Agg max >50% Agg max ≤50% 100%40% 60% Angiolillo DJ et al. Circulation. 2007;115: %

DrugTypeRouteActionDose Mean Platelet Inhibition ( Time Required ) ( Time Required )Trials (Phase III) Prasugrel(CS-747) Thienopyridine (3 rd gen) – requires hepatic conversion to active metabolite Oral Irreversible binding 60 mg loading dose, 10 mg maintenance dose ≈ 70% (<1 hour) TRITON AZD6140 Cyclopetyl- triazolopy- rimidine – Direct inhibition Oral Competitive binding 90 mg bid ≈ 95% (2-4 hours) PLATO Cangrelor(ARC MX) ATP analogue – Direct inhibition Parenteral Competitive binding 4 μg/kg/min ≈ 95% (few minutes) CHAMPION Novel P2Y 12 ADP Receptor Antagonist More potent and less variability!! Angiolillo DJ et al. J Am Coll Cardiol. 2007; 49: